MARKET WIRESeeking Alpha • 1d ago
Precipio: Management Dreams Big, Institutions Have A Toe In (NASDAQ:PRPO)Seeking Alpha report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
Why PRPO Stock slipped -1.71% Today — RQD Quant Desk Flash
$17.79 -1.71% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $17.70
Precipio Inc. (PRPO) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $32.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PRPO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Precipio Inc. (NASDAQ: PRPO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $17.79 (-1.71% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, PRPO ranks #810 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PRPO compare to EYPT and RPID in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PRPO?
▼
Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $17.70 (-0.50%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 1.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRPO)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY PRPO SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+9/20 pts (30% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 31.3 (OVERSOLD (<32))
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$22.59-3.9% Next Q
38
Q2 (-2Q)Grade E$21.72-12.9% Next Q
35
Q3 (-1Q)Grade E$18.91-5.9% Next Q
33
CurrentGrade E$17.79-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PRPO Turnaround Squeeze
While PRPO currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.10) and Max Pain ($18.68) forces dealer call-delta covering toward $35.31.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRPO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRPO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PRPO Stock slipped -1.71% Today — RQD Quant Desk Flash
Precipio Inc. (PRPO) slipped -1.71% to $17.79, trading at 2% of its 52-week range ($17.99 – $33.63). Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($17.99 – $33.63) with RSI-14 at 31.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.3% around $17.79 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 44.2% gross margin and $359000 annual free cash flow.
Live PRPO Headlines & Catalysts
MARKET WIREBenzinga • 1d ago
Precipio Announces Q3-2026 Shareholder Update CallBenzinga report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Precipio to Discuss Products Revenue Milestone at Nov. 10 Shareholder CallTradingView report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Traders Daily • 1d ago
(PRPO) Price Dynamics and Execution-Aware PositioningStock Traders Daily report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
Responsive Playbooks and the PRPO InflectionStock Traders Daily report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
PRPO Q2 2025 Earnings: Positive $0.05 EPS as Shares Slide 2.9% - Tax Rate Impacthttps://www.dars.gov.et/ report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETipRanks • 2d ago
Precipio Announces Q3 2026 Shareholder Update CallTipRanks report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeekingAlpha • 22d ago
Precipio: Management Dreams Big, Institutions Have A Toe InPrecipio (PRPO) stock update: razor/razor-blades cancer diagnostics, insider + Vanguard/BlackRock ownership, breakeven cash flow, 30% growth.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRPO)
- ✓Walkthrough of PRPO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PRPO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -40.10%▼ DESCENDING CHANNEL
2026-11-03O $19.35H $19.35L $17.79C $17.79VOL 25.9K
RES: $31.91SUP: $15.22SMA50: $24.10SMA200: $24.94
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PRPO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +30.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on PRPO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PRPO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRPO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRPO)
Health Care Rank #810 of 1015
⚔️ EYPT vs PRPO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PRPO vs. EYPT, RPID, HBIO, BNGO)
Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Precipio Inc. (PRPO) ranks #810 by composite RQD confidence (30/100, grade E) and #788 by equity capitalization ($32.4M). Within this direct 5-issuer industry benchmark cohort, PRPO leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with PRPO at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRPO
ACTIVE
Precipio Inc. | E | 30/100 | — | 44.2% | -7.9% | -1.71% | $32.4M | Benchmark Subject |
| EYPT EyePoint Inc. | E | 26/100 | — | — | -35.0% | +7.58% | $30.0M | /eypt-vs-prpo → |
| RPID Rapid Micro Biosystems Inc. (Class A) | E | 34/100 | — | — | -35.0% | -4.50% | $36.9M | /rpid-vs-prpo → |
| HBIO Harvard Bioscience Inc. | D | 47/100 | — | 57.7% | -35.0% | -3.37% | $40.5M | /hbio-vs-prpo → |
| BNGO Bionano Genomics Inc. | E | 29/100 | — | 46.3% | -35.0% | +0.87% | $16.1M | /bngo-vs-prpo → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001043961 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Precipio Inc. (PRPO) reported GAAP revenue of $24.2M (+30.5% vs. FY2024 revenue of $18.6M , and +57.3% cumulative change since FY2023) , GAAP net income of -$363.0K, operating cash flow of $685.0K, and free cash flow of $359.0K (+66.2% YoY). On the balance sheet, PRPO closed FY2025 with $21.3M in total assets against $47.0K in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $24.2M | -$363.0K | $685.0K | $359.0K | $21.3M | $47.0K |
| FY2024 (FY) | 2024-12-31 | $18.6M | -$4.3M | $439.0K | $216.0K | $17.0M | $77.0K |
| FY2023 (FY) | 2023-12-31 | $15.4M | -$5.9M | -$3.6M | -$3.6M | — | — |
3. PRPO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PRPO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Precipio Inc. (NASDAQ: PRPO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $17.79 (-1.71% 1D, market cap $32.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, PRPO ranks #810 in composite RQD confidence.
How does PRPO compare to EYPT and RPID in the Health Care sector?
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), PRPO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 44.2%, and ROIC of -7.9%. By comparison, EYPT (EyePoint Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M) and RPID (Rapid Micro Biosystems Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $36.9M). Among the 5-stock peer group, PRPO leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PRPO?
Per PRPO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001043961), Precipio Inc. generated $24.2M in revenue (+30.5% YoY), -$363.0K in net income, and $359.0K in free cash flow against $21.3M in total assets and $47.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PRPO trading relative to its 50-day, 200-day, and 52-week technical levels?
PRPO last traded at $17.79 (-1.71% on volume of 12,784 shares), positioning the stock -26.18% below its 50-day simple moving average ($24.10) and -28.67% below its 200-day simple moving average ($24.94). Across its 52-week range of $17.99 to $33.63, PRPO sits at the 0.0% percentile with a 14-day RSI of 31.3 (OVERSOLD (<32)) and an implied next-earnings move of ±10.3% ($15.96 to $19.62).
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ SEC XBRL & RQD VERIFIED
PRPO — Precipio Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Precipio Inc. (PRPO) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $17.79 (-1.71% 1D, market capitalization $32.4M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -7.9%, gross margin of 44.2%, operating margin of -5.0%, and free cash flow yield of 1.04%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 8/9, and Debt/Equity of 0.00x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Precipio Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry..0B, which is inconsistent with the $34.6M figure in the market data section.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Precipio Inc. (PRPO) reported $24.2M in annual revenue (up from $18.6M in FY2024, +30.5% YoY) and -$363.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($15.4M revenue, -$5.9M net income) through FY2025, PRPO scaled operating cash flow to $685.0K and free cash flow to $359.0K, backed by $21.3M in total assets against $47.0K in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.04% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $17.99 – $33.63 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -5.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), PRPO carries a macro regime beta of 1.00 and gross margin of 44.2%.
- Key Question #1: Can PRPO sustain or expand its -5.0% operating margin and -7.9% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $24.2M and free cash flow of $359.0K, how will capital allocation balance growth reinvestment against $47.0K in total debt?
- Key Question #3: How sensitive is PRPO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
PRPO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Precipio Inc. (PRPO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 1d ago
Precipio: Management Dreams Big, Institutions Have A Toe In (NASDAQ:PRPO) Seeking Alpha report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Precipio Announces Q3-2026 Shareholder Update Call Benzinga report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Precipio to Discuss Products Revenue Milestone at Nov. 10 Shareholder Call TradingView report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Traders Daily • 1d ago
(PRPO) Price Dynamics and Execution-Aware Positioning Stock Traders Daily report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
Responsive Playbooks and the PRPO Inflection Stock Traders Daily report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
PRPO Q2 2025 Earnings: Positive $0.05 EPS as Shares Slide 2.9% - Tax Rate Impact https://www.dars.gov.et/ report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TipRanks • 2d ago
Precipio Announces Q3 2026 Shareholder Update Call TipRanks report covering Precipio Inc. (PRPO) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST SeekingAlpha • 22d ago
Precipio: Management Dreams Big, Institutions Have A Toe In Precipio (PRPO) stock update: razor/razor-blades cancer diagnostics, insider + Vanguard/BlackRock ownership, breakeven cash flow, 30% growth.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PRPO Bull vs. Bear Conversation Board — What's Your Call at $17.79?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRPO 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $21.36 (+18.0%)
📌 Pinned Debate Revenue grew from $15.4M in FY 2023 to $24.2M in FY 2025 while operating losses narrowed from -$7.6M to -$1.2M, and the Piotroski F-Sco
Here is why I am bullish on PRPO here at $18.10: Revenue grew from $15.4M in FY 2023 to $24.2M in FY 2025 while operating losses narrowed from -$7.6M to -$1.2M, and the Piotroski F-Score of 8 out of 9 signals strong operating quality.. Compare PRPO's -5.0% operating margin and -7.9% ROIC against the rest of Biotechnology: Laboratory Analytical Instruments. As long as cash conversion holds up, dips toward $17.20 are getting bought.
EarningsSniper 🐂 BULL
@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $18.10 is dangerous when funds are rotating into Health Care.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $13.76 (-24.0%)
Spot @ $18.10 With an Altman Z-Score of 0.2, ROIC of -7.9%, and an FCF yield of 1.04%, the company shows distress-zone solvency signals and weak cash
With an Altman Z-Score of 0.2, ROIC of -7.9%, and an FCF yield of 1.04%, the company shows distress-zone solvency signals and weak cash returns alongside a 3 out of 20 Whale 13F Flow score.. Look at the math on PRPO: paying current EV/EBITDA multiples for -7.9% ROIC and -5.0% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $15.93 before getting long.